-0.22%
6.49%
-2.48%
-6.98%
4.56%
-12.98%
-2.00%
AI Spotlight on COLO
Company Description
Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally.The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments.It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system.In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution.Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence.
Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand.The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
Market Data
| Last Price | 834 |
| Change Percentage | -0.22% |
| Open | 834.4 |
| Previous Close | 835.8 |
| Market Cap ( Millions) | 186797 |
| Volume | 14780 |
| Year High | 977.6 |
| Year Low | 772 |
| M A 50 | 825.14 |
| M A 200 | 865.31 |
Financial Ratios
| FCF Yield | 0.79% |
| Dividend Yield | 1.20% |
| ROE | 30.72% |
| Debt / Equity | 126.12% |
| Net Debt / EBIDTA | 254.11% |
| Price To Book | 10.46 |
| Price Earnings Ratio | 37.14 |
| Price To FCF | 126.9 |
| Price To sales | 6.91 |
| EV / EBITDA | 24.27 |
News
- Jan -22 - Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction)
- Jan -21 - Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET
- Dec -05 - Coloplast A/S - Decisions at the Annual General Meeting 2024
- Dec -04 - Coloplast divests core Skin Care product portfolio
- Nov -14 - Kerecis included on the list of covered products for Diabetic Foot Ulcers in the final LCD policy
- Nov -12 - Coloplast A/S - Notice of Annual General Meeting 2024
- Nov -06 - Coloplast AS (CLPBF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ...
- Nov -05 - Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24
- Nov -05 - Coloplast A/S - Full-Year Financial Results 2023/24
- Nov -05 - Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive Leadership Team
- Oct -21 - Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on 5 November 2024 at 11.00 CET
- Aug -22 - Recent Price Trend in Coloplast A/S Sponsored ADR (CLPBY) is Your Friend, Here's Why
- Aug -20 - Coloplast A/S - Interim Financial Report, 9M 2023/24
- May -17 - Coloplast A/S's Dividend Analysis
- May -16 - Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June 2024 (gentle reminder)
- May -14 - Coloplast expands its Luja™ portfolio with next generation catheter for women
- May -10 - Stocks to watch this week: Burberry, Vodafone, BT and Walmart
- May -07 - Coloplast strengthens ostomy care portfolio with three significant product launches
- May -07 - Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24
- Apr -26 - Stocks to watch this week: Amazon, Apple, Anglo American and Novo Nordisk
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Chronic Care
Expected Growth : 7 %
What the company do ?
Chronic Care from Coloplast A/S provides innovative solutions for people with intimate healthcare needs, such as ostomy care, continence care, and wound care.
Why we expect these perspectives ?
Chronic Care from Coloplast A/S driven by increasing prevalence of chronic diseases, aging population, and rising healthcare expenditure. Growing demand for homecare and self-care products, innovative product offerings, and strategic acquisitions also contribute to the 7% growth. Furthermore, expansion into emerging markets and favorable reimbursement policies support the segment's growth.
Segment n°2 -> Advanced wound Dressings
Expected Growth : 9 %
What the company do ?
Advanced wound dressings from Coloplast A/S are innovative, evidence-based solutions that promote optimal wound healing, comfort, and convenience for patients and caregivers.
Why we expect these perspectives ?
Coloplast A/S's advanced wound dressings growth is driven by increasing prevalence of chronic wounds, rising demand for effective wound care, and growing adoption of advanced technologies. Additionally, expanding healthcare infrastructure, aging population, and increasing focus on patient outcomes are contributing to the 9% growth rate.
Segment n°3 -> Interventional Urology
Expected Growth : 6 %
What the company do ?
Interventional Urology from Coloplast A/S refers to minimally invasive procedures and devices for treating urological conditions, such as kidney stones and prostate cancer.
Why we expect these perspectives ?
Strong demand for minimally invasive treatments, increasing prevalence of urological disorders, and innovative product launches drive Coloplast's Interventional Urology segment growth. Expanding presence in emerging markets, strategic partnerships, and investments in R&D further fuel growth. Additionally, the rising adoption of robotic-assisted surgeries and growing focus on patient outcomes contribute to the segment's 6% growth.
Segment n°4 -> Voice and Respiratory Care
Expected Growth : 5 %
What the company do ?
Voice and Respiratory Care from Coloplast A/S provides tracheostomy and oxygen therapy solutions, supporting patients with respiratory needs and promoting independence.
Why we expect these perspectives ?
Coloplast's Voice and Respiratory Care segment growth is driven by increasing demand for respiratory solutions, expansion into emerging markets, and innovative product launches. Additionally, the rising prevalence of respiratory diseases, such as COPD and asthma, and the growing need for voice rehabilitation solutions also contribute to the segment's growth.
Segment n°5 -> Biologics
Expected Growth : 8 %
What the company do ?
Biologics from Coloplast A/S are tissue-engineered products used for soft tissue repair and reconstruction, promoting natural healing and tissue regeneration.
Why we expect these perspectives ?
Coloplast A/S's biologics segment growth is driven by increasing demand for wound care and surgical treatments, expansion into emerging markets, and strategic partnerships. Additionally, investments in R&D and product innovation, such as advanced wound dressings and surgical implant technologies, contribute to the segment's growth.
Coloplast A/S Products
| Product Range | What is it ? |
|---|---|
| Ostomy Care | Coloplast's Ostomy Care products are designed to help people with ostomies to live a normal life, with a range of pouches, accessories, and accessories for colostomy, ileostomy, and urostomy. |
| Continence Care | Coloplast's Continence Care products are designed to help people with urinary incontinence, including catheters, leg bags, and accessories. |
| Wound & Skin Care | Coloplast's Wound & Skin Care products are designed to promote wound healing and skin health, including dressings, creams, and cleansers. |
| Intermittent Catheters | Coloplast's Intermittent Catheters are designed for people who require intermittent catheterization, providing a convenient and discreet way to manage their bladder. |
| Male Urology | Coloplast's Male Urology products are designed to help men with urological conditions, including erectile dysfunction and benign prostatic hyperplasia (BPH). |
Coloplast A/S's Porter Forces
Threat Of Substitutes
The threat of substitutes for Coloplast A/S is medium due to the presence of alternative products and services in the market, but the company's strong brand reputation and product differentiation mitigate this threat.
Bargaining Power Of Customers
The bargaining power of customers for Coloplast A/S is low due to the company's strong relationships with its customers and the lack of buyer concentration in the market.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Coloplast A/S is medium due to the presence of multiple suppliers in the market, but the company's large scale of operations and strong relationships with suppliers mitigate this threat.
Threat Of New Entrants
The threat of new entrants for Coloplast A/S is low due to the high barriers to entry in the market, including regulatory hurdles and the need for significant capital investment.
Intensity Of Rivalry
The intensity of rivalry for Coloplast A/S is high due to the presence of several established competitors in the market, leading to a highly competitive environment.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 53.08% |
| Debt Cost | 4.11% |
| Equity Weight | 46.92% |
| Equity Cost | 5.54% |
| WACC | 4.78% |
| Leverage | 113.11% |
Coloplast A/S : Quality Control
Coloplast A/S passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| EL.PA | EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, Latin America, Asia, Oceania, and Africa. It operates in five segments: Wholesale, Retail, Lenses … |
| DIM.PA | Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a … |
| VBSN.SW | IVF Hartmann Holding AG provides medical consumer goods in Switzerland and internationally. The company offers surgical disposable instruments, blankets, clothing and gloves, disinfection and hygiene products, wound management and hydrotherapy … |
| SAN.PA | Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, … |
| STMN.SW | Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Sanofi
A-Score
1-Year Total Return ->
🥈
IVF Hartmann Holding
A-Score
1-Year Total Return ->
🥉
EssilorLuxottica
A-Score
1-Year Total Return ->
4
Coloplast
A-Score
1-Year Total Return ->
5
Straumann
A-Score
1-Year Total Return ->
6
